Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 102. More products

PREGABALIN

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N02BF) — coverage varies; not interchangeable

  • Gabapentin (Neurontin): general benefit, Not a benefit

AG-Pregabalin · DIN 02480727 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AG-Pregabalin · DIN 02480727 Manufacturer: Angita Pharma Inc.; listing date 2020-11-30 Health Canada: Marketed since 2018-09-28 · brand AG-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Angita pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

AG-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97125 · Verify on the e-Formulary ↗ (DIN 02480727)

Source record
DIN 02480727: AG-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id ANG Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02480727 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97125
Interchangeable products
Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02480727
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Pregabalin · DIN 02449838 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Pregabalin · DIN 02449838 Manufacturer: Accord Healthcare Inc.; listing date 2021-08-31 Health Canada: Marketed since 2021-05-27 · brand ACH-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93569 · Verify on the e-Formulary ↗ (DIN 02449838)

Source record
DIN 02449838: Ach-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id ACH Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449838 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93569
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended 2023-11-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449838
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Pregabalin · DIN 02433869 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Pregabalin · DIN 02433869 Manufacturer: Auro Pharma Inc.; listing date 2015-05-28 Health Canada: Marketed since 2015-03-02 · brand AURO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91825 · Verify on the e-Formulary ↗ (DIN 02433869)

Source record
DIN 02433869: Auro-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id AUR Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02433869 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91825
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended 2021-01-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02433869
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Pregabalin · DIN 02541122 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Pregabalin · DIN 02541122 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2024-02-29 · brand BIO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Biomed pharma · schedule Prescription
Check this DIN again · Health Canada product record

Bio-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102979 · Verify on the e-Formulary ↗ (DIN 02541122)

Source record
DIN 02541122: Bio-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id BMP Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541122 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102979
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541122
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Pregabalin · DIN 02435977 · 25mg · capsule

General benefitMarketed · checked 2026-09-20
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Pregabalin · DIN 02435977 Manufacturer: Jamp Pharma Corporation; listing date 2016-01-28 Health Canada: Marketed since 2019-10-01 · brand JAMP-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92031 · Verify on the e-Formulary ↗ (DIN 02435977)

Source record
DIN 02435977: Jamp-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id JPC Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02435977 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92031
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02435977
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lyrica · DIN 02268418 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Lyrica (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lyrica · DIN 02268418 Manufacturer: Upjohn Canada ULC; listing date 2013-04-30 Health Canada: Marketed since 2023-05-11 · brand LYRICA · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75379 · Verify on the e-Formulary ↗ (DIN 02268418)

Source record
DIN 02268418: Lyrica Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id UJC Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $1.0222; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02268418 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75379
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended 2025-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268418
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Pregabalin · DIN 02467291 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Pregabalin · DIN 02467291 Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30 Health Canada: Marketed since 2023-10-06 · brand M-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95568 · Verify on the e-Formulary ↗ (DIN 02467291)

Source record
DIN 02467291: M-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id MAT Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467291 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95568
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended 2022-01-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02467291
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Pregabalin · DIN 02417529 · 25mg · capsule

General benefitMarketed · checked 2026-09-20
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Pregabalin · DIN 02417529 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-05-29 Health Canada: Marketed since 2022-04-28 · brand MAR-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90207 · Verify on the e-Formulary ↗ (DIN 02417529)

Source record
DIN 02417529: Mar-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id MAR Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417529 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90207
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: active shortage (reported 2017-10-01, last updated 2018-07-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417529
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Pregabalin · DIN 02423804 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Pregabalin · DIN 02423804 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-08-28 Health Canada: Marketed since 2014-06-12 · brand MINT-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90851 · Verify on the e-Formulary ↗ (DIN 02423804)

Source record
DIN 02423804: Mint-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id MIN Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423804 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90851
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended 2018-02-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02423804
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Pregabalin · DIN 02479117 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Pregabalin · DIN 02479117 Manufacturer: Nora Pharma; listing date 2020-07-31 Health Canada: Marketed since 2018-10-22 · brand NRA-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96708 · Verify on the e-Formulary ↗ (DIN 02479117)

Source record
DIN 02479117: NRA-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id NRA Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479117 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96708
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479117
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nat-Pregabalin · DIN 02494841 · 25mg · capsule

General benefitMarketed · checked 2026-09-20
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Nat-Pregabalin · DIN 02494841 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-02-28 Health Canada: Marketed since 2020-05-07 · brand NAT-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Natco pharma (canada) inc · schedule Prescription
Check this DIN again · Health Canada product record

Nat-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98482 · Verify on the e-Formulary ↗ (DIN 02494841)

Source record
DIN 02494841: Nat-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id NAT Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494841 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98482
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494841
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Pregabalin · DIN 02359596 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Pregabalin · DIN 02359596 Manufacturer: Pharmascience Inc.; listing date 2013-04-30 Health Canada: Marketed since 2013-02-14 · brand PMS-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84460 · Verify on the e-Formulary ↗ (DIN 02359596)

Source record
DIN 02359596: PMS-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id PMS Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02359596 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84460
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended 2018-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02359596
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pregabalin · DIN 02403692 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Pregabalin · DIN 02403692 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-07-31 Health Canada: Marketed since 2021-08-20 · brand PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88848 · Verify on the e-Formulary ↗ (DIN 02403692)

Source record
DIN 02403692: Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id SIV Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02403692 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88848
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: Reversed (report reversed by the reporter); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02403692
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pregabalin · DIN 02405539 · 25mg · capsule

General benefitMarketed · checked 2026-09-20
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Pregabalin · DIN 02405539 Manufacturer: Sanis Health Inc.; listing date 2016-05-31 Health Canada: Marketed since 2016-01-27 · brand PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89032 · Verify on the e-Formulary ↗ (DIN 02405539)

Source record
DIN 02405539: Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id SAI Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405539 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89032
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended 2024-03-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02405539
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Pregabalin · DIN 02392801 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Pregabalin · DIN 02392801 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2013-04-30 Health Canada: Marketed since 2020-06-02 · brand TARO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87804 · Verify on the e-Formulary ↗ (DIN 02392801)

Source record
DIN 02392801: Ran-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id RAN Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02392801 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87804
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: active shortage (reported 2026-02-11, estimated to end 2026-09-25, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392801
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Pregabalin · DIN 02390817 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Pregabalin · DIN 02390817 Manufacturer: Sandoz Canada Inc.; listing date 2013-04-30 Health Canada: Marketed since 2013-02-15 · brand SANDOZ PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87621 · Verify on the e-Formulary ↗ (DIN 02390817)

Source record
DIN 02390817: Sandoz Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id SDZ Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390817 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87621
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended 2026-03-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02390817
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Pregabalin · DIN 02361159 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Pregabalin · DIN 02361159 Manufacturer: Teva Canada Limited; listing date 2013-04-30 Health Canada: Marketed since 2013-03-06 · brand TEVA-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Pregabalin: Formulary list price $0.1481/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1481 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84620 · Verify on the e-Formulary ↗ (DIN 02361159)

Source record
DIN 02361159: Teva-Pregabalin Raw flags: sec3=Y Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id TEV Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1481; ministry $0.1481 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361159 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84620
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481 Ach-Pregabalin · DIN 02449838 · $0.1481 Apo-Pregabalin · DIN 02394235 · $0.1481 Auro-Pregabalin · DIN 02433869 · $0.1481 Bio-Pregabalin · DIN 02541122 · $0.1481 Co Pregabalin · DIN 02402912 · $0.1481 Jamp-Pregabalin · DIN 02435977 · $0.1481 Lyrica · DIN 02268418 · $0.1481 M-Pregabalin · DIN 02467291 · $0.1481 Mar-Pregabalin · DIN 02417529 · $0.1481 Mint-Pregabalin · DIN 02423804 · $0.1481 NRA-Pregabalin · DIN 02479117 · $0.1481 Nat-Pregabalin · DIN 02494841 · $0.1481 PMS-Pregabalin · DIN 02359596 · $0.1481 Pregabalin · DIN 02403692 · $0.1481 Pregabalin · DIN 02405539 · $0.1481 Ran-Pregabalin · DIN 02392801 · $0.1481 Sandoz Pregabalin · DIN 02390817 · $0.1481
Shortage status: discontinued (2022-03-23, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361159
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AG-Pregabalin · DIN 02480735 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AG-Pregabalin · DIN 02480735 Manufacturer: Angita Pharma Inc.; listing date 2020-11-30 Health Canada: Marketed since 2018-09-28 · brand AG-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Angita pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

AG-Pregabalin: Formulary list price $0.2324/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2324 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97126 · Verify on the e-Formulary ↗ (DIN 02480735)

Source record
DIN 02480735: AG-Pregabalin Raw flags: sec3=Y Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id ANG Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2324; ministry $0.2324 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02480735 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97126
Interchangeable products
Ach-Pregabalin · DIN 02449846 · $0.2324 Apo-Pregabalin · DIN 02394243 · $0.2324 Auro-Pregabalin · DIN 02433877 · $0.2324 Bio-Pregabalin · DIN 02541130 · $0.2324 Co Pregabalin · DIN 02402920 · $0.2324 Jamp-Pregabalin · DIN 02435985 · $0.2324 Lyrica · DIN 02268426 · $0.2324 M-Pregabalin · DIN 02467305 · $0.2324 Mar-Pregabalin · DIN 02417537 · $0.2324 Mint-Pregabalin · DIN 02423812 · $0.2324 NRA-Pregabalin · DIN 02479125 · $0.2324 Nat-Pregabalin · DIN 02494868 · $0.2324 PMS-Pregabalin · DIN 02359618 · $0.2324 Pregabalin · DIN 02403706 · $0.2324 Pregabalin · DIN 02405547 · $0.2324 Ran-Pregabalin · DIN 02392828 · $0.2324 Sandoz Pregabalin · DIN 02390825 · $0.2324 Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02480735
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Pregabalin · DIN 02449846 · 50mg · capsule

General benefitMarketed · checked 2026-09-20
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Pregabalin · DIN 02449846 Manufacturer: Accord Healthcare Inc.; listing date 2021-08-31 Health Canada: Marketed since 2021-05-27 · brand ACH-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Pregabalin: Formulary list price $0.2324/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2324 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93570 · Verify on the e-Formulary ↗ (DIN 02449846)

Source record
DIN 02449846: Ach-Pregabalin Raw flags: sec3=Y Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id ACH Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2324; ministry $0.2324 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449846 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93570
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324 Apo-Pregabalin · DIN 02394243 · $0.2324 Auro-Pregabalin · DIN 02433877 · $0.2324 Bio-Pregabalin · DIN 02541130 · $0.2324 Co Pregabalin · DIN 02402920 · $0.2324 Jamp-Pregabalin · DIN 02435985 · $0.2324 Lyrica · DIN 02268426 · $0.2324 M-Pregabalin · DIN 02467305 · $0.2324 Mar-Pregabalin · DIN 02417537 · $0.2324 Mint-Pregabalin · DIN 02423812 · $0.2324 NRA-Pregabalin · DIN 02479125 · $0.2324 Nat-Pregabalin · DIN 02494868 · $0.2324 PMS-Pregabalin · DIN 02359618 · $0.2324 Pregabalin · DIN 02403706 · $0.2324 Pregabalin · DIN 02405547 · $0.2324 Ran-Pregabalin · DIN 02392828 · $0.2324 Sandoz Pregabalin · DIN 02390825 · $0.2324 Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: resolved shortage (ended 2026-09-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449846
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Pregabalin · DIN 02394243 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Pregabalin · DIN 02394243 Manufacturer: Apotex Inc.; listing date 2013-04-30 Health Canada: Marketed since 2026-08-14 · brand APO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Pregabalin: Formulary list price $0.2324/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2324 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87940 · Verify on the e-Formulary ↗ (DIN 02394243)

Source record
DIN 02394243: Apo-Pregabalin Raw flags: sec3=Y Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id APX Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2324; ministry $0.2324 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394243 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87940
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324 Ach-Pregabalin · DIN 02449846 · $0.2324 Auro-Pregabalin · DIN 02433877 · $0.2324 Bio-Pregabalin · DIN 02541130 · $0.2324 Co Pregabalin · DIN 02402920 · $0.2324 Jamp-Pregabalin · DIN 02435985 · $0.2324 Lyrica · DIN 02268426 · $0.2324 M-Pregabalin · DIN 02467305 · $0.2324 Mar-Pregabalin · DIN 02417537 · $0.2324 Mint-Pregabalin · DIN 02423812 · $0.2324 NRA-Pregabalin · DIN 02479125 · $0.2324 Nat-Pregabalin · DIN 02494868 · $0.2324 PMS-Pregabalin · DIN 02359618 · $0.2324 Pregabalin · DIN 02403706 · $0.2324 Pregabalin · DIN 02405547 · $0.2324 Ran-Pregabalin · DIN 02392828 · $0.2324 Sandoz Pregabalin · DIN 02390825 · $0.2324 Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: active shortage (reported 2024-11-12, last updated 2024-11-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394243
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Pregabalin · DIN 02433877 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Pregabalin · DIN 02433877 Manufacturer: Auro Pharma Inc.; listing date 2015-05-28 Health Canada: Marketed since 2015-03-02 · brand AURO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Pregabalin: Formulary list price $0.2324/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2324 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91826 · Verify on the e-Formulary ↗ (DIN 02433877)

Source record
DIN 02433877: Auro-Pregabalin Raw flags: sec3=Y Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id AUR Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2324; ministry $0.2324 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02433877 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91826
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324 Ach-Pregabalin · DIN 02449846 · $0.2324 Apo-Pregabalin · DIN 02394243 · $0.2324 Bio-Pregabalin · DIN 02541130 · $0.2324 Co Pregabalin · DIN 02402920 · $0.2324 Jamp-Pregabalin · DIN 02435985 · $0.2324 Lyrica · DIN 02268426 · $0.2324 M-Pregabalin · DIN 02467305 · $0.2324 Mar-Pregabalin · DIN 02417537 · $0.2324 Mint-Pregabalin · DIN 02423812 · $0.2324 NRA-Pregabalin · DIN 02479125 · $0.2324 Nat-Pregabalin · DIN 02494868 · $0.2324 PMS-Pregabalin · DIN 02359618 · $0.2324 Pregabalin · DIN 02403706 · $0.2324 Pregabalin · DIN 02405547 · $0.2324 Ran-Pregabalin · DIN 02392828 · $0.2324 Sandoz Pregabalin · DIN 02390825 · $0.2324 Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: resolved shortage (ended 2021-02-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02433877
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Pregabalin · DIN 02541130 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Pregabalin · DIN 02541130 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2024-03-11 · brand BIO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Biomed pharma · schedule Prescription
Check this DIN again · Health Canada product record

Bio-Pregabalin: Formulary list price $0.2324/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2324 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102980 · Verify on the e-Formulary ↗ (DIN 02541130)

Source record
DIN 02541130: Bio-Pregabalin Raw flags: sec3=Y Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id BMP Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2324; ministry $0.2324 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541130 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102980
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324 Ach-Pregabalin · DIN 02449846 · $0.2324 Apo-Pregabalin · DIN 02394243 · $0.2324 Auro-Pregabalin · DIN 02433877 · $0.2324 Co Pregabalin · DIN 02402920 · $0.2324 Jamp-Pregabalin · DIN 02435985 · $0.2324 Lyrica · DIN 02268426 · $0.2324 M-Pregabalin · DIN 02467305 · $0.2324 Mar-Pregabalin · DIN 02417537 · $0.2324 Mint-Pregabalin · DIN 02423812 · $0.2324 NRA-Pregabalin · DIN 02479125 · $0.2324 Nat-Pregabalin · DIN 02494868 · $0.2324 PMS-Pregabalin · DIN 02359618 · $0.2324 Pregabalin · DIN 02403706 · $0.2324 Pregabalin · DIN 02405547 · $0.2324 Ran-Pregabalin · DIN 02392828 · $0.2324 Sandoz Pregabalin · DIN 02390825 · $0.2324 Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541130
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Pregabalin · DIN 02435985 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Pregabalin · DIN 02435985 Manufacturer: Jamp Pharma Corporation; listing date 2016-01-28 Health Canada: Marketed since 2018-07-25 · brand JAMP-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Pregabalin: Formulary list price $0.2324/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2324 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92032 · Verify on the e-Formulary ↗ (DIN 02435985)

Source record
DIN 02435985: Jamp-Pregabalin Raw flags: sec3=Y Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id JPC Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2324; ministry $0.2324 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02435985 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92032
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324 Ach-Pregabalin · DIN 02449846 · $0.2324 Apo-Pregabalin · DIN 02394243 · $0.2324 Auro-Pregabalin · DIN 02433877 · $0.2324 Bio-Pregabalin · DIN 02541130 · $0.2324 Co Pregabalin · DIN 02402920 · $0.2324 Lyrica · DIN 02268426 · $0.2324 M-Pregabalin · DIN 02467305 · $0.2324 Mar-Pregabalin · DIN 02417537 · $0.2324 Mint-Pregabalin · DIN 02423812 · $0.2324 NRA-Pregabalin · DIN 02479125 · $0.2324 Nat-Pregabalin · DIN 02494868 · $0.2324 PMS-Pregabalin · DIN 02359618 · $0.2324 Pregabalin · DIN 02403706 · $0.2324 Pregabalin · DIN 02405547 · $0.2324 Ran-Pregabalin · DIN 02392828 · $0.2324 Sandoz Pregabalin · DIN 02390825 · $0.2324 Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02435985
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lyrica · DIN 02268426 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Lyrica (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lyrica · DIN 02268426 Manufacturer: Upjohn Canada ULC; listing date 2013-04-30 Health Canada: Marketed since 2023-05-11 · brand LYRICA · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2324 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75380 · Verify on the e-Formulary ↗ (DIN 02268426)

Source record
DIN 02268426: Lyrica Raw flags: sec3=Y Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id UJC Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.6034; ministry $0.2324 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02268426 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75380
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324 Ach-Pregabalin · DIN 02449846 · $0.2324 Apo-Pregabalin · DIN 02394243 · $0.2324 Auro-Pregabalin · DIN 02433877 · $0.2324 Bio-Pregabalin · DIN 02541130 · $0.2324 Co Pregabalin · DIN 02402920 · $0.2324 Jamp-Pregabalin · DIN 02435985 · $0.2324 M-Pregabalin · DIN 02467305 · $0.2324 Mar-Pregabalin · DIN 02417537 · $0.2324 Mint-Pregabalin · DIN 02423812 · $0.2324 NRA-Pregabalin · DIN 02479125 · $0.2324 Nat-Pregabalin · DIN 02494868 · $0.2324 PMS-Pregabalin · DIN 02359618 · $0.2324 Pregabalin · DIN 02403706 · $0.2324 Pregabalin · DIN 02405547 · $0.2324 Ran-Pregabalin · DIN 02392828 · $0.2324 Sandoz Pregabalin · DIN 02390825 · $0.2324 Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: resolved shortage (ended 2026-05-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268426
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

GABAPENTIN

· 69 products · General benefit (49), Off-Formulary Interchangeable, not an ODB benefit (20) · strengths: 100mg, 300mg, 400mg, 600mg, 800mg · Cap, Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L

VALPROIC ACID

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain associated with fibromyalgia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. DULOXETINE · Listed, not a benefit (2), General benefit (36) • Fibromyalgia pms-DULOXETINE is indicated for the management of pain associated with fibromyalgia (FM). PM: https://pdf.hres.ca/dpd_pm/00084896.PDF; date 2026-05-29; DIN 02429446; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Adults LYRICA (pregabalin capsules) is indicated for the management of neuropathic pain associated with: • Diabetic peripheral neuropathy; • Postherpetic neuralgia; • Spinal cord injury LYRICA is indicated for the management of pain associated with fibromyalgia. The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics: Pregabalin oral clearance tended to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with age-related decreases in creatinine clearance. Reduction of pregabalin dose may be required in patients who have age-related compromised renal function (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00074814.PDF PM date: MAR 4, 2024 Source product: LYRICA; DIN 02268418; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Mar-Pregabalin · DIN 02417529 Shortage status: active shortage (reported 2017-10-01, last updated 2018-07-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417529

Check this DIN again

Ran-Pregabalin · DIN 02392801 Shortage status: active shortage (reported 2026-02-11, estimated to end 2026-09-25, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392801

Check this DIN again

Teva-Pregabalin · DIN 02361159 Shortage status: discontinued (2022-03-23, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361159

Check this DIN again

Apo-Pregabalin · DIN 02394243 Shortage status: active shortage (reported 2024-11-12, last updated 2024-11-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394243

Check this DIN again